Emcure, Roche Partner to Boost Kidney Transplant, Anemia Therapies in India

• Emcure Pharmaceuticals and Roche signed a distribution agreement on March 2 to distribute select nephrology and transplant care products in India.
• The agreement, effective April 1, 2026, covers Roche's established brands like CellCept (immunosuppressant) and Mircera, Neorecormon (anemia therapies for CKD).
• Emcure's MD & CEO, Satish Mehta, stated the partnership aims to improve outcomes in anemia and renal care by expanding access to critical therapies.
• Roche India's MD & CEO, Rajji Mehdwan, highlighted Emcure's strong distribution network to reach more patients with Roche's innovations.
• The collaboration expands patient access to therapies in chronic kidney disease, anemia management, and transplant care, complementing Emcure's existing offerings.